Saturday, November 22, 2008

Rheumatoid Arthritis Home>
Rheumatoid Arthritis News>
Drugmaker halts development of new RA drug

Drugmaker halts development of new RA drug

(Reuters) UPDATED 2008-10-09

Drugmaker Biogen has announced that it is halting development of a new rheumatoid arthritis (RA) medication. The drug, baminercept, failed to show that it was effective at treating RA in a mid-stage clinical trial. Biogen officials say they will continue to study the data on the drug and will present it at an upcoming scientific meeting. Read full story >

See all Rheumatoid Arthritis News

Bookmark

Was this helpful? Yes

Save to My Home
Want to keep this page handy for later? Click Save to My Home and we'll add it to your My Home area.

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on MyRACentral.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2008. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.